Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with Ulcerative Colitis. Companies like AbbVie [Skyrizi (Risankizumab)], Eli Lilly and Company [Mirikizumab (LY-3074828)], Arena Pharmaceuticals [Etrasimod], Janssen (Johnson & Johnson) [Tremfya (Guselkumab)], InDex Pharmaceuticals [Corbitolimod] and several others are developing therapies which are in the clinical development stage for Ulcerative Colitis.
DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ulcerative Colitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Ulcerative Colitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Ulcerative Colitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Ulcerative Colitis: An Overview
Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. The exact cause of IBD is unknown, but it is the result of a defective immune system.
Two major types of IBD are Ulcerative Colitis (UC) and Crohn's Disease (CD). UC is limited to the colon or large intestine. CD, on the other hand, can involve any part of the gastrointestinal tract from the mouth to the anus. Approximately 10% of cases of IBD exhibit the features of both CD and UC. These are typically known as Indeterminate Colitis (IC). There are different types of Ulcerative Colitis, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis.
Symptoms of Ulcerative Colitis can range from mild to extreme and vary from individual to individual. They can also change over time, when the symptoms are troublesome, with periods of recovery where a person has good health and no symptoms, alternating with relapses or flare-ups.
Ulcerative Colitis Market Key Facts
-
The total prevalent population of Ulcerative Colitis in the 7MM in 2022 was ~2,223,000. These cases are expected to rise by 2032, during the forecast period [2023–2032].
-
In EU4 and the UK, in 2022, there were a total of ~1,024,000 prevalent cases and ~740,000 diagnosed prevalent cases of Ulcerative Colitis.
-
The total diagnosed cases of Ulcerative Colitis in the 7MM were ~1,615,100 in 2022.
-
In the 7MM, ~45% mild and ~55% moderate-to-severe cases of Ulcerative Colitis were observed in 2022.
-
In the 7MM, the United States reported the highest prevalent cases of Ulcerative Colitis, i.e., ~1,026,000 which accounted for nearly 46% of the total 7MM cases, in the year 2022.
-
Among the EU4 and the UK, the highest number of cases of Ulcerative Colitis was in Germany, i.e. ~357,000 cases in 2022.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Ulcerative Colitis pipeline therapies. It also thoroughly assesses the Ulcerative Colitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Ulcerative Colitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Ulcerative Colitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Ulcerative Colitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Ulcerative Colitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Ulcerative Colitis Epidemiology, Segmented as -
-
Total Prevalent Cases of Ulcerative Colitis in the 7MM [2019–2032]
-
Severity-specific Cases of Ulcerative Colitis in the 7MM [2019–2032]
-
Total Diagnosed Cases of Ulcerative Colitis in the 7MM [2019–2032]
-
Age-specific Cases of Ulcerative Colitis in the 7MM [2019–2032]
Ulcerative Colitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Ulcerative Colitis market or expected to be launched during the study period. The analysis covers the Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Ulcerative Colitis drugs based on their sale and market share.
The report also covers the Ulcerative Colitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Ulcerative Colitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Ulcerative Colitis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market
Ulcerative Colitis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Ulcerative Colitis. Currently, Gilead Sciences is leading the therapeutics market with its Ulcerative Colitis drug candidates in the most advanced stage of clinical development.
Ulcerative Colitis Companies Actively Working in the Therapeutics Market Include
Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, Prometheus Biosciences, PNB Vesper Life Science, Pandion Therapeutics, Palatin Technologies, Theravance Biopharma, VHsquared, Seres Therapeutics, Hoffmann-La Roche, Provention Bio, Bacainn Therapeutics, Landos Biopharma, Bristol-Myers Squibb, Janssen Research & Development, GlaxoSmithKline, Assembly Biosciences, NuBiyota, and many others.
Emerging and Marketed Ulcerative Colitis Therapies Covered in the Report Include:
-
Mirikizumab: Eli Lilly and Company
-
Risankizumab: AbbVie
-
Etrasimod: Pfizer
-
Skyrizi (Risankizumab): AbbVie
-
Mirikizumab (LY-3074828): Eli Lilly and Company
-
Etrasimod: Arena Pharmaceuticals
-
Tremfya (Guselkumab): Janssen (Johnson & Johnson)
-
SHR0302: Reistone Biopharma
-
BT-11: Landos Biopharma
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Ulcerative Colitis Competitive Intelligence Analysis
4. Ulcerative Colitis Market Overview at a Glance
5. Ulcerative Colitis Disease Background and Overview
6. Ulcerative Colitis Patient Journey
7. Ulcerative Colitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Ulcerative Colitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Ulcerative Colitis Unmet Needs
10. Key Endpoints of Ulcerative Colitis Treatment
11. Ulcerative Colitis Marketed Therapies
12. Ulcerative Colitis Emerging Drugs and Latest Therapeutic Advances
13. Ulcerative Colitis Seven Major Market Analysis
14. Attribute Analysis
15. Ulcerative Colitis Market Outlook (In US, EU5, and Japan)
16. Ulcerative Colitis Companies Active in the Market
17. Ulcerative Colitis Access and Reimbursement Overview
18. KOL Views on the Ulcerative Colitis Market
19. Ulcerative Colitis Market Drivers
20. Ulcerative Colitis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Campylobacter Infections Market
"Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032" report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Campylobacter Infections market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Campylobacter Infections market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
